Introduction
Liquid biopsy is the vision of easy blood sampling to monitor a cancer patient's disease status at any time point, but will it come true soon for routine patient care? The idea of liquid biopsy is not restricted to oncology but applicable to prenatal diagnostics [1] , cardiovascular diseases [2] or atherosclerosis [3] . Liquid biopsy of blood samples in oncology includes intact cells, cell-free nucleic acids or other components, e.g. exosomes that are shed into the bloodstream by tumors and/or metastatic deposits [4] (fig. 1.) .
Circulating Tumor Cells
Circulating tumor cells (CTCs) were first described in the mid of the 19th century by the Australian pathologist Ashworth, who discovered cells similar to those of the tumor in a patient's blood after death [9] . Up to now, a mass of studies has been published on CTCs and their clinical relevance, and a huge scientific research field on that topic has evolved [10] . CTCs are of particular interest because these cells succeeded in extravasating from the tumor into the circulation and might potentially intravasate into distant tissues to form overt metastases. A deep analysis of these metastasisinitiating cells [11] might help to decipher the molecular processes of the metastatic cascade [12] . A crucial step for intravasation and survival in the bloodstream for a cell is to gain plasticity and motility, which involves the process of epithelial-mesenchymal transition (EMT). During EMT, the epithelial cell adhesion molecule (EpCAM) may be downregulated. As it is widely used as a marker to enrich CTCs, there is a need for techniques that also accurately capture the more mesenchymal fraction of CTCs. Several approaches have been made to address this issue and some of them have even been tested in first clinical studies [13] .
A variety of techniques for analyzing CTCs in blood have been developed over the last few years and are discussed in detail elsewhere [14] . The purposes that CTC detection and characterization can fulfill in oncology are diverse. Importantly, CTC positivity is a prognostic marker for disease outcome in different carcinomas, and identifies patients with minimal residual disease who are at risk of recurrence [15] [16] [17] . Moreover, CTC analyses might serve to guide treatment decisions by predicting the response to pharmaceutical agents in individual patients based on their particular molecular disease signature, e.g. the expression of the androgen receptor variant V7 (AR-V7) in castration-resistant prostate cancer (CRPC) [18] . During the course of therapy, CTC detection can be used as a surrogate marker for response, e.g. in CRPC [19] and breast cancer [20] . Interestingly, Yu and colleagues [21] found a dynamic predominance of either epithelial or mesenchymal-like CTCs in times of treatment response or progression, respectively, in metastatic breast cancer patients. Additionally, they observed the presence of CTC clusters. For scientific interest, in-depth analyses of CTC characteristics on DNA, RNA and protein levels will help in understanding the biology of the metastatic process and deciphering therapy-resistance mechanisms. To facilitate functional studies, a higher number of cells is imperative. So far, cell lines from CTCs, e.g. of colon [22] and breast cancer [23] patients, as well as xenografts from CTCs of breast and lung cancer patients [11, 24, 25] , have been successfully established and might be applied for in vitro and in vivo drug testing.
Circulating Cell-Free Nucleic Acids
Apoptotic and necrotic tumor cells are known to discharge cellfree nucleic acid fragments (cfDNA, cfRNA and cfmiRNA) into the bloodstream of cancer patients. Moreover, active secretion of cfDNA in exosomes as well as the release of digested fragments by macrophages after phagocytosis of apoptotic and necrotic cells have been suggested [26] . Although most circulating DNA is believed to originate from non-malignant cells, an increased level of cfDNA was found in the blood of late stage cancer patients [27] . Circulating tumor DNA (ctDNA) cannot be specifically isolated from the pool of total cfDNA, but the detection of tumor-specific mutations indicate its presence [5] . In addition to the primary tumor, micro-metastatic deposits or CTCs can also potentially contribute to the release of ctDNA, so that it reflects all subclones present in a single patient [26] .
In general, cfDNA can be analyzed from plasma by targeted or untargeted approaches, as discussed elsewhere [28, 29] . The targeted approaches involve the detection of known genetic changes, e.g. 'druggable' mutations, with impact on therapy decisions [30] .
Interestingly, the study of Murtaza and colleagues [31] revealed the acquisition of secondary drug resistance during disease course by monitoring clonal evolution in 6 advanced cancer patients for 1-2 years. Douillard et al. [32] showed that cfDNA has clinical utility in determining the epidermal growth factor receptor (EGFR) mutational status in non-small cell lung cancer (NSCLC), and can represent a substitute for tissue biopsies when these are not available. In 2016, the detection of EGFR gene mutations in cfDNA using the Cobas EGFR Mutation Test v2 achieved FDA approval as a companion diagnostic for Erlotinib, becoming the first blood-based biopsy test approved for implementation in clinical decisions [33] .
The primary tumor analysis is still the gold standard in NSCLC diagnostics of EGFR (and other) mutations because of the lower sensitivity of ctDNA analyses. However, it has been recommended (e.g. by the FDA) that the blood could be analyzed first to reduce the number of invasive biopsies in cancer patients. Because cfRNA is less stable in blood than cfDNA when it is not incorporated into protecting vesicles [26] , there are only few approaches to analyze it as part of a liquid biopsy. Qin et al. [34] made an attempt to stabilize cfRNA using novel blood collection tubes. The clinical significance of cfRNA was investigated by the group of Pucciarelli [35] who demonstrated a significant prediction of response to preoperative chemoradiotherapy (pCRT) in rectal cancer patients using RT-PCR. In a microarray-based study on CRPC patients, a 9-gene signature significantly correlated with poorer overall survival [36] .
MicroRNAs (miRNAs, miR-x) are also strongly linked to the pathogenesis of most human malignancies [37] and circulating cellfree miRNAs (cfmiRNAs) have been established as a new marker in liquid biopsy in oncology [38] . They consist of approximately 22 nucleotides, are more stable in blood than cfRNA, and are probably resistant to endogenous RNase activity due to coupling to argonaute 2 (AGO2) complexes of most cfmiRNAs [39] . The 3 major detection techniques following RNA extraction comprise quantitative RT-PCR, microarray analyses and deep sequencing [38] . The assessment of cfmiRNA has been suggested for therapy monitoring and response prediction, as reviewed by Schwarzenbach and colleagues [38] .
Exosomes and Tumor-Educated Platelets
One challenge in analyzing circulating cell-free nucleic acids is their instability in blood. Tumors as well as normal cells are known to additionally discharge cellular content into the circulation by releasing microvesicles such as exosomes (40-150 nm). Due to the protective environment, exosomes are a valuable source for analysis of contained proteins, DNA, RNA, miRNA, lipids and metabolites [40] . Exosomes can be isolated either by ultracentrifugation, density-based separation or immune-affinity capture using magnetic beads coated with anti-EpCAM antibodies [41] . Hoshino et al. [42] demonstrated that the composition of exosomal integrins could predict organ-specific metastasis and that tumor-derived exosomes participate in preparing the pre-metastatic niche. Correspondingly, a pro-metastatic phenotype of bone marrow progenitor cells is promoted by education through melanoma exosomes as shown by Peinado and colleagues [43] .
Another new class of components for liquid biopsy are tumoreducated platelets (TEPs) [44] . These anucleated cell fragments form the second most-abundant cell type in peripheral blood and can be educated by tumor cells by the transfer of tumor-associated biomolecules, mostly RNA. Platelets are isolated by centrifugation and RNA can be subjected to RT-PCR [45] . Best and colleagues [46] showed by performing mRNA sequencing on TEPs that cancer patients of diverse entities could be discriminated from healthy individuals with 96% accuracy, and that the location of the primary tumor was correctly identified with a precision of 71%. Furthermore, biomarkers (MET or HER2 expression/KRAS, EGFR and PIK3CA mutations) were identified in surrogate TEP mRNA profiles, which might be tested in future studies as potential predictors for targeted therapies.
Conclusions and Future Perspectives
Liquid biopsy has evolved to a very active research field, and in particular CTCs and cfDNA have gained remarkable attention as biomarkers. Despite important advances, the clinical utility of liquid biopsy is still under debate and some technical challenges remain to be solved. CTC and ctDNA detection is not equally feasible in all tumor entities, and there is also some inter-patient variability among patients with the same tumor entity. For example, in NSCLC the amount of CTCs and ctDNA is much lower than expected for such an aggressive disease with high metastatic potential [47, 48] .
Moreover, some patients with a substantial burden of gross metastasis harbor low amounts of CTCs or ctDNA [28, 49] . The most difficult site of primary or metastatic tumor growth is the brain, probably due to the blood-brain barrier that may shield cells and cell products from entering the blood in high quantities as compared to other organs [28] .
Thus far, it remains unclear to what extent this reflects tumor biology or improper technologies, e.g. the use of epithelial markers in patients with carcinomas that have undergone a considerable degree of EMT [13] . Regarding cell-free nucleic acids in blood, only a small percentage is really tumor derived. The vast majority of these molecules originate from dying normal cells, and this 'dilution' can be substantial during cytotoxic cancer therapies that kill not only cancer cells but also normal tissues [26, 38] , and cfDNA levels can be affected by stress and intense exercise [50] . A better understanding of these confounding factors of liquid biopsy analyses will be important to improve our current diagnostic capabilities. Before implementation in routine patient care, the assays need to be validated, which is a key aim of the European CANCER-ID consortium (www.cancer-id.eu). Quality management of liquid biopsy tests is of utmost importance.
CTCs offer the entire range of analyses at the DNA, RNA and protein level, and allow also functional studies (e.g. drug testing) on viable cells in vitro and in vivo. The disadvantage is the low concentration of CTCs in many patients, in particular at earlier disease stages. Exosomes analysis also allows a similar range of descriptive analysis but is functionally limited. ctDNA analysis is restricted to druggable mutations mainly derived from apoptotic cells that may not always represent the therapy-resistant viable tumor cell clone in cancer patients [51] . However, recent work on ctDNA and tumor-derived exosomes isolated from blood plasma samples have also faced the same challenge [28, 47, 48] . Nevertheless, blood plasma samples are easier to store for retrospective evaluations, although the pre-analytical variables are also very important to obtain sufficient quantities of ctDNA and avoid dilution with normal DNA from dying blood cells. The work on tumor-associated platelets is rather new and the advantages and disadvantages are still under investigation. One limitation of RNA analysis in platelets might be the fragility of RNA molecules during shipment of clinical samples.
Large clinical trials are ongoing to show clinical utility [52] . While the clinical applications of liquid biopsy to predict relapse and steer therapy in patients with diagnosed cancer are constantly becoming more evident [49] , its application for early cancer detection still remains a substantial challenge [33, 53, 54] . Even a minor lack in assay specificity would lead to numerous false-positive results, causing avoidable concern of patients and enormous subsequent diagnosis costs, while false-negative results would retard important therapeutic interventions. Large prospective cohort studies are required to verify if the identified mutations indeed indicate a malignant disease and, inversely, if a lack of mutation confirms an absence of cancer.
In conclusion, the various liquid biopsy platforms reviewed here may potentially complement each other for the management of cancer patients. Sequential real-time liquid biopsies will have the potential for early identification of resistance to cancer therapy in individual patients as an important hallmark of personalized cancer medicine [55] . Moreover, detection and characterization of minimal residual disease after initial therapy is another important aim and challenge for future studies [56] .
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